Survey
* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
Syllabus for Clinical Aspects of Hematopoietic Stem Cell Transplantation for OVMC Fellows 5/2017 Reading List: ASCO-SEP Chapter on Hematopoietic Cell Transplantation ASH-SAP Chapter on Clinical bone marrow and stem cell transplantation ASH CME Quiz Useful Texts/Resources: Blood and Marrow Transplant Handbook: Comprehensive Guide for Patient Care 2nd ed. 2015 Edition Thomas' Hematopoietic Cell Transplantation, 2 Volume Set 5th Edition Hematopoietic Stem Cell Transplantation: A Handbook for Clinicians, 2nd edition 2nd Edition Part One: Hematopoietic Transplantation 1. Overview of the Stem Cell Transplant Process a. Which diseases are appropriate for HSCT? b. Patient selection c. Donor selection d. Conditioning e. GVHD Prophylaxis 2. Stem Cell Source a. Peripheral Blood Stem Cells b. Bone Marrow 3. Donor Selection a. HLA Match – Matched Related, Matched Unrelated, Haploidentical b. Female Donors c. Donor-Specific Antibodies d. Donor Age e. Killer-like Immunoglobulin (KIR) Matching 4. Conditioning Regimens a. Anti-Malignancy Effect b. Immunosuppression c. Use of TBI d. Intensity & Toxicity i. Myeloablative ii. Reduce-Intensity iii. Non-Myeloablative 5. GVHD Prophylaxis a. Tacrolimus – Methotrexate b. ATG c. Post-transplant Cyclophosphamide 6. Day 0 – Engraftment a. Definition of Engraftment b. Delayed Engraftment / Primary Graft Failure c. Regimen-Related Toxicity i. Mucositis ii. VOD 1. Risk factors for VOD 2. Diagnosis 3. Management d. Sepsis / Infection e. PRESS / Tacro toxicity f. Fluid Overload g. TMA 7. Engraftment – Day 100 a. Secondary Graft Failure b. Viral Reactivation c. Fungal Infection d. Immunosuppression vs Immune Reconstitution e. Acute GVHD 8. Management of Acute GVHD a. Diagnosis b. Grading c. Management 9. CMV Reactivation 10. Chronic GVHD a. Diagnosis b. Grading c. Management 11. Late Effects / Survivorship a. Iron Overload b. Infections c. Relapse i. Monitoring / MRD Testing ii. Prophylaxis (TKI, hypomethylator) iii. Donor Lymphocyte Infusions iv. Second Allogeneic Transplant d. Secondary Malignancies Part Two: Transplantation for Specific Diseases 1. AML a. Disease Risk Stratification b. Role of Conditioning Intensity c. GVM effect 2. ALL a. Disease Risk Stratification & Impact of Blinatumomab and Inotuzumab b. Role of Conditioning Intensity c. GVM effect 3. CML 4. CLL? 5. MDS 6. Indolent Lymphoma a. Role of CAR-T b. Role of Targeted Therapies / Ibrutinib 7. DLBCL 8. Mantle Cell Lymphoma 9. Hodgkin Lymphoma 10. Multiple Myeloma 11. Aplastic Anemia